JP2023525991A5 - - Google Patents

Info

Publication number
JP2023525991A5
JP2023525991A5 JP2022567223A JP2022567223A JP2023525991A5 JP 2023525991 A5 JP2023525991 A5 JP 2023525991A5 JP 2022567223 A JP2022567223 A JP 2022567223A JP 2022567223 A JP2022567223 A JP 2022567223A JP 2023525991 A5 JP2023525991 A5 JP 2023525991A5
Authority
JP
Japan
Prior art keywords
seq
chain variable
variable region
polypeptide sequence
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022567223A
Other languages
English (en)
Japanese (ja)
Other versions
JP7821121B2 (ja
JP2023525991A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/031055 external-priority patent/WO2021226321A2/en
Publication of JP2023525991A publication Critical patent/JP2023525991A/ja
Publication of JP2023525991A5 publication Critical patent/JP2023525991A5/ja
Application granted granted Critical
Publication of JP7821121B2 publication Critical patent/JP7821121B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022567223A 2020-05-07 2021-05-06 抗腫瘍関連抗原抗体及びその使用 Active JP7821121B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202063021215P 2020-05-07 2020-05-07
US63/021,215 2020-05-07
US202062706131P 2020-08-03 2020-08-03
US62/706,131 2020-08-03
US202063198420P 2020-10-16 2020-10-16
US63/198,420 2020-10-16
US202063131394P 2020-12-29 2020-12-29
US63/131,394 2020-12-29
PCT/US2021/031055 WO2021226321A2 (en) 2020-05-07 2021-05-06 Anti-tumor associated antigen antibodies and uses thereof

Publications (3)

Publication Number Publication Date
JP2023525991A JP2023525991A (ja) 2023-06-20
JP2023525991A5 true JP2023525991A5 (https=) 2024-05-20
JP7821121B2 JP7821121B2 (ja) 2026-02-26

Family

ID=78468388

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022567223A Active JP7821121B2 (ja) 2020-05-07 2021-05-06 抗腫瘍関連抗原抗体及びその使用

Country Status (11)

Country Link
US (1) US20230220107A1 (https=)
EP (1) EP4146702A4 (https=)
JP (1) JP7821121B2 (https=)
KR (1) KR20230007452A (https=)
CN (1) CN115515981A (https=)
AU (1) AU2021267893A1 (https=)
BR (1) BR112022020716A2 (https=)
CA (1) CA3173176A1 (https=)
IL (1) IL297955A (https=)
MX (1) MX2022013920A (https=)
WO (1) WO2021226321A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10980836B1 (en) 2019-12-11 2021-04-20 Myeloid Therapeutics, Inc. Therapeutic cell compositions and methods of manufacturing and use thereof
WO2022197949A2 (en) 2021-03-17 2022-09-22 Myeloid Therapeutics, Inc. Engineered chimeric fusion protein compositions and methods of use thereof
TW202426058A (zh) * 2022-10-18 2024-07-01 加拿大商酵活英屬哥倫比亞有限公司 靶向磷脂醯肌醇蛋白聚糖－３之抗體－藥物結合物及使用方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004022597A1 (ja) * 2002-09-04 2004-03-18 Chugai Seiyaku Kabushiki Kaisha Gpc3の血中可溶化ｎ端ﾍﾟﾌﾟﾁﾄﾞに対する抗体
ME02345B (me) * 2007-07-17 2016-08-31 Squibb & Sons Llc MONOKLONSKA ANTlTELA PROTIV GLIPIKANA-3
EP2699603B1 (en) * 2011-04-19 2016-03-02 The United States of America As Represented by the Secretary Department of Health and Human Services Human monoclonal antibodies specific for glypican-3 and use thereof
WO2015179658A2 (en) * 2014-05-22 2015-11-26 Genentech, Inc. Anti-gpc3 antibodies and immunoconjugates
MA40764A (fr) * 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
TW201713700A (zh) * 2015-05-27 2017-04-16 台灣泰福生技股份有限公司 抗ｇｌｙｐｉｃａｎ-３抗體及其用於診斷及治療癌症之用途
US11072666B2 (en) * 2016-03-14 2021-07-27 Chugai Seiyaku Kabushiki Kaisha Cell injury inducing therapeutic drug for use in cancer therapy
US11767362B1 (en) * 2016-03-15 2023-09-26 Chugai Seiyaku Kabushiki Kaisha Methods of treating cancers using PD-1 axis binding antagonists and anti-GPC3 antibodies
WO2017162587A1 (en) * 2016-03-22 2017-09-28 F. Hoffmann-La Roche Ag Protease-activated t cell bispecific molecules
US11299708B2 (en) * 2016-05-12 2022-04-12 Adicet Bio, Inc. Methods for selective expansion of γδ T-cell populations and compositions thereof
UA128383C2 (uk) * 2016-12-07 2024-07-03 Дженентек, Інк. Антитіло до тау-білка та спосіб його застосування
EP3615574A4 (en) * 2017-04-26 2021-02-24 Eureka Therapeutics, Inc. SPECIFIC GLYPICAN 3 RECOGNIZING CONSTRUCTS AND THEIR USE
WO2019059411A1 (en) * 2017-09-20 2019-03-28 Chugai Seiyaku Kabushiki Kaisha DOSAGE FOR POLYTHERAPY USING PD-1 AXIS BINDING ANTAGONISTS AND GPC3 TARGETING AGENT
AR114112A1 (es) * 2018-02-15 2020-07-22 Seattle Genetics Inc Anticuerpos de glipicano 3 y conjugados de los mismos
CN111040036B (zh) * 2018-10-12 2023-10-20 上海卡智生物技术有限公司 抗gpc3单克隆抗体、由其修饰的免疫效应细胞及其应用

Similar Documents

Publication Publication Date Title
JP2021514664A5 (https=)
CN112867507B (zh) 新型抗sirpa抗体
IL276830B1 (en) Anti-claudin 18.2 antibodies and their uses
CN102209730B (zh) 抗cxcr4抗体及其用于治疗癌症的用途
JP2021008487A (ja) 抗ｎｋｇ２ａ抗体を使用した治療計画
JP2020510422A5 (https=)
JP2022527173A5 (https=)
JP2022526420A5 (https=)
JP2024531409A5 (https=)
CN102939306B (zh) 用于治疗癌症的人源化抗cxcr4抗体
IL310938A (en) Anti-CCR8 antibodies and their uses
JP2010532169A5 (https=)
JP2021528047A5 (https=)
RU2014101669A (ru) Агенты, связывающие белки r-спондины (rspo), и способы их применения
HRP20150256T1 (hr) Djelatna sredstva za vezanje notch1-receptora i postupci njihove uporabe
JP2022526841A5 (https=)
JP2024521472A5 (https=)
JP2023525991A5 (https=)
CN114181310A (zh) 抗tigit抗体、其药物组合物及用途
KR20240039006A (ko) 신규 항-sirpa 항체
JP7663265B2 (ja) 抗ＳＩＲＰα抗体またはその抗原結合断片および適用
CA3208473A1 (en) Pharmaceutical composition and use thereof
US20250215087A1 (en) Combination therapy of kras inhibitor and treg depleting agent
CN112969715B (zh) 一种抗cd47抗原结合蛋白及其应用
AU2019306113B2 (en) Anti-human PD-L1 antibodies and their uses